BOLALARDA ATOPIK DERMATITNING KOMORBID KECHISHI XAVF OMILLARI VA KLINIK XUSUSIYATLARI
Abstrakt
Atopik dermatit multifaktorial kasallik bo‘lib, kelib chiqishida organizmdagi irsiy o‘zgarishlar va trigger mexanizmlarni birgalikdagi ta’siri natijasida yuzaga keladi. Ma’lumki, multifaktorial kasalliklarni etiopatogenetik «asosi» ma’lum bir polimorf shaklli, funksional nuqsonli gen (genetik «moyillik», gen-nomzodlar, gen-vositachilar) larni yaratib, atrof muhitga zararli ta’siri ko‘rsatadi. Tarixiy manbalarga asoslanib, atopik dermatit organizmning ingalyasion va oziq-ovqat allergenlariga «noodatiy» genetik determinatsiyalashgan reaksiyasi bo‘lib, javob tariqasida immunoglobulin E (IgE) va spetsifik IgE-antitanachalarining miqdorini ortishi bilan xarakterlanadi.Bizning bugungi ishimizda atopik dermatitni kelib chiqishi va boshqa allergik kasalliklar bilan komorbit kechishi xavf omillari yoritilgandir. Tadqiqot materiallari va usullari. 2019-2024 yillarda Toshkent tibbiyot akademiyasining ko‘p tarmoqli klinikasida yotib davolangan 6-12 yoshdagi 130 nafar BA va AtD bilan kasallangan bolalar olingan. Tadqiqot natijalari. atopik dermatitni BA bilan komorbid kechishi rivojlanishining tibbiy biologik va ijtimoiy xavf omillari aniqlangan;atopik dermatitni BA bilan komorbid kechishini erta tashxislash uchun peshobda Cys-LT miqdorini aniqlash muximligi asoslangan;atopik dermatitni BA bilan komorbid kechishini erta tashxislash usuli ishlab chiqilgan, davolash usuli takomillashtirilgan va uning samaradorligi peshobdagi leykotriyenlar va qondagi maxsus IgE miqdorini aniqlashga asoslangan. Xulosa. Atopik dermatitni bronxial astma bilan komorbid kechishining klinik ko‘rinishlarini aniqlash, tashxislash va davolash usullarini takomillashtirish bo‘yicha olingan ilmiy natijalar asosida:bolalarda atopik dermatitni bronxial astma bilan komorbid kechishida, davolash usullarini optimallashtirish va birlamchi bo‘g‘inga tadbiq qilish.
Mualliflar haqida
Adabiyotlar ro'yxati
Atopic dermatitis: clinical guidelines. - 2020. [Atopicheskii dermatit: Clinical guidelines.(InRuss).] Available at: https://nrcii.ru/specialistam/klinrecommend/atopic_dermatitis_2020.pdf. The link is active on 09.24.2022.
Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. 2015;136(3):667–677.e7. doi: https://doi.org/ 10.1016/j.jaci.2015.03.051
Wollenberg A, Ehmann LM. Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema. Ann Dermatol. 2012;24(3):253.doi: https://doi.org/10.5021/ad.2012.24.3.253
Amat F, Soria A, Tallon P, et al. New insights into the phenotypes of atopic dermatitis linked with allergies and asthma in children: An overview. Clin Exp Allergy. 2018;48(8):919–934. doi: https://doi.org/10.1111/cea.13156
Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi: https://doi.org/10.1111/jdv.14891
Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016;138(2):350–358. doi: https://doi.org/10.1016/j.jaci.2016.06.002
Granato L. Modulator from fractions of vegetable unsaponifiables.Personal Care. 2012;09:69–72.
Mirraximova M. X. et al. Night of atopic dermatitis in children komorbid laboratory-immunological properties //IMRAS. – 2023. – Т. 6. – №. 6. – С. 301-306.
Kh M. M., Kurbanova D. R., Nishanbaeva N. Y. Identification of clinical and laboratory changes of the gastrointestinal tract in atopic dermatitis in children and improvement of the principles of diagnosis and treatment/ISSN 2181-712X.
Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march.Biochem Med (Zagreb). 2019;29(2):214–227. doi: https://doi.org/10.11613/bm.2019.0205
Man MQ, Barish GD, Schmuth M, et al. Deficiency of PPARbeta/ delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J Invest Dermatol. 2008;128(2):370–377. doi: https://doi.org/10.1038/ sj.jid.5701026
Tominaga M, Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications. J Dermatol. 2014;41(3):205–212. doi: https://doi.org/10.1111/ 1346-8138.12317
Kido-Nakahara M, Furue M, Ulzii D, Nakahara T. Itch in Atopic Dermatitis. Immunol Allergy Clin North Am. 2017;37(1):113–122. doi: https://doi.org/10.1016/j.iac.2016.08.007
Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014;134(4):792–799. doi: https://doi.org/10.1016/j.jaci.2014.06.014
Dale BA, Presland RB, Lewis SP, et al. Transient Expression of Epidermal Filaggrin in Cultured Cells Causes Collapse of Interme diate Filament Networks with Alteration of Cell Shape and Nuclear Integrity.J Invest Dermatol. 1997;108(2):179–187. doi: https://doi.org/ 10.1111/1523-1747.ep12334205
Stout TE, McFarland T, Mitchell JC, et al. Recombinant filaggrin is in - ternalized and processed to correct filaggrin deficiency. J Invest Der ma tol. 2014;134(2):423–429. doi: https://doi.org/10.1038/jid.2013.284
Kim JH, Bae HC, Ko NY, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol. 2015;136(1):205–208.e9. doi: https://doi.org/10.1016/j.jaci.2015.04.026
Pellerin L, Henry J, Hsu CY, et al. Defects of filaggrin-like proteins in both lesional and nonlesional atopic skin. J Allergy Clin Immunol. 2013;131(4):1094–1102. doi: https://doi.org/10.1016/j.jaci.2012.12.1566
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.